An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

Full Study Title: An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

Summary

The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.

Participant Eligibility

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Diagnosis of JIA (any subtype)
  • Age < 18 years at the time of enrollment unless currently or previously enrolled in an abatacept clinical trial and received abatacept
  • Receiving Abatacept at the time of enrollment as per treating physician’s decision or received abatacept in a clinical trial
  • Parent or legally acceptable representative willing to participate in the study and sign the informed consent

Exclusion Criteria:

  • Pregnant or nursing female at the time of enrollment
  • Prior malignancies if the patient has not been malignancy free for at least 5 years.
  • Any serious acute or chronic medical condition other than JIA, including chronic infection, which would compromise the patient’s ability to participate in the study
  • Known poor compliance with clinic visits (based on physician judgment)

Study ID: NCT01357668

Study Sites
Medical College of Wisconsin

Principal Investigator(s)
Bristol-Myers Squibb

Contact
James Nocton
414-266-6792
jnocton@mcw.edu



CTSI PARTNERS

VersitiChildren's Hospital of WisconsinVA Medical CenterMarquette UniversityMSOEUWM